Drug Trial Radar · NCT06975748
A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis
Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jun 12, 2025
Primary completion
Apr 2026
Study completion Apr 2026
Sponsor
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- May 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, double-blind, placebo-controlled study to evaluate the safety and efficacy of STSP-0902 ophthalmic solution in patients with neurotrophic keratitis (NK). The study plans to enroll 48 patients with Mackie Stage 2 or 3 NK affecting one or both eyes. Eligible subjects will be randomized 1:1:1 into three dosing groups. Each dosing group will follow a drug-placebo allocation (12 active: 4 placebo). Treatment involves topical ocular administration for 8 weeks. Subjects who are not healed after the 8 weeks of masked treatment period will be permitted to receive standard of care during the follow-up period
Conditions
- Neurotrophic Keratitis
Interventions
STSP-0902 ophthalmic solutionDrug
Eye drop, 3 times daily for 8 weeks
STSP-0902 ophthalmic solutionDrug
Eye drop, 6 times daily for 8 weeks
STSP-0902 PlaceboDrug
Eye drop, 3 or 6 times daily for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse EventsTime frame: Screening to Week 10
- Ocular Symptoms and SignsTime frame: Screening to Week 10
- Intraocular Pressure (IOP) MeasurementsTime frame: Screening to Week 10
- Slit-Lamp ExaminationsTime frame: Screening to Week 10
- Optical Coherence Tomography (OCT) ResultsTime frame: Screening to Week 10
- Clinically Significant Changes in Vital SignsTime frame: Screening to Week 10
- Clinically Significant Changes in Physical ExaminationsTime frame: Screening to Week 10
- Clinically Significant Changes in 12-Lead ECGsTime frame: Screening to Week 10
- Clinically Significant Laboratory AbnormalitiesTime frame: Screening to Week 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shandong First Medical University Affiliated Eye Hospital
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.